Latest App Notes & Case Studies

The high resolution and scale that single cell analysis provides is revolutionizing drug discovery and development by introducing comparative, longitudinal and causal information that transforms our ability to understand biology and disease.

Studying tissue and organ biology is challenging, particularly in mammals, given sample accessibility and ethical concerns. However, the use of organoids alleviates these challenges, supporting researchers in exploring questions that previously could not have been investigated without them.

Download this app note to discover immunoassay platforms that are consistent for your cell therapy and immunology development needs.

Triple negative breast cancer (TNBC) is unresponsive to traditional hormone or targeted therapies and highly heterogeneous. Improved understanding of the biological underpinnings and cell-type composition of TNBC is critical to developing novel targeted treatment options.

This technical note provides a comprehensive LC-MS proteomic analysis to detect and monitor COVID-19 infection severity and disease progression.

Download this app note to explore various solutions designed to improve COVID-19 detection and the development of vaccines and therapeutics.

Download this app note to discover a fluorescent-based approach that can enable real-time measurement of viral gene expression and be used to study virtually any virus in a 96- or 384- well format.

Affibodies are synthetic antigen-binding proteins. They offer many advantages over monoclonal antibodies, including smaller sizes, enhanced thermal stability and rapid refolding capability. These advantages make affibodies an attractive platform for the development of therapeutics, diagnostics and bioimaging technology.

Viruses exploit high-dimensional RNA structures to facilitate viral replication and impede host restriction. Here, a novel next-generation sequencing (NGS)-based screening workflow, called Fate-seq, was used to define and characterize high-dimensional RNA structures.

Therapeutic monoclonal antibodies (mAbs) are highly heterogeneous molecules due to being composed of a large number of variants. When the variants are present in the pharmaceutical protein, it is possible their biological activity could be altered.